Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Rheumatoid arthritis test, 7/13:105

Crescendo Bioscience announced that the Wadsworth Center at the New York Department of Health, through its Clinical Laboratory Evaluation Program, issued a laboratory permit to Crescendo Bioscience to provide services to physicians in New York. Crescendo offers Vectra DA, a multi-biomarker blood test that measures disease activity in rheumatoid arthritis by integrating 12 key proteins consistently associated with the biology of RA into one objective, quantitative score to help physicians make more informed patient management decisions. Vectra DA is now

Beta-hydroxybutyric acid linearity control, 7/13:105

Audit MicroControls has added to its line of calibration verification/linearity products, the beta-hydroxybutyric acid linearity, five levels. The control is intended to simulate human patient serum samples for determining linearity, calibration verification, and verification of reportable range for beta-hydroxybutyric acid. Packaged as 5 × 1 mL, this liquid product has a shelf life of two years and an open-vial stability of seven days when stored at 2° to 8°C. Audit MicroControls, 866-252-8348

Erlotinib tablets and EGFR mutation test, 7/13:104

The FDA has approved Roche Diagnostics’ Tarceva (erlotinib) tablets for the initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR)-activating mutations as detected by an FDA-approved test. The FDA also approved Roche’s Cobas EGFR mutation test. In the United States, Tarceva is already approved, irrespective of histology or biomarker status, for people with advanced-stage NSCLC whose cancer has not spread or grown after initial treatment with certain types of

Parasite detection kits, 7/13:104

Boulder Diagnostics has launched in Europe its ParaFlor kits for the detection of Giardia, Cryptosporidium, and Blastocystis infections for human and veterinary applications. The rapid assays enable detection in less than 10 minutes in fresh and fixed stool samples. They are also available for veterinary applications and research use only in humans in the United States. The ParaFlor B kit is the first specific assay for the detection of the Blastocystis parasite. Boulder Diagnostics, 720-897-6276

Microscope illuminator, 7/13:104

ScopeLED, a division of Dicon Fiberoptics, has released its LED-based fluorescence microscope illuminator, which is designed to fit most clinical fluorescence microscopes. The ScopeLED F-series illuminators mount directly to the microscope’s fluorescence illuminator and look like a standard microscope lamp house. With more than 30,000 hours of LED lifetime, no maintenance should be required for over 12 to 15 years of heavy lab usage. Power consumption is under 5 W per hour compared to more than 300 W per hour

Anti-CCP test for arthritis, 7/13:104

Siemens Healthcare Diagnostics has obtained FDA clearance for its anti-cyclic citrullinated peptide (anti-CCP) IgG assay to aid diagnosis of rheumatoid arthritis (RA). Available on the company’s Immulite 2000/2000 XPi immunoassay systems, the assay enables laboratories to integrate RA testing onto an automated, random-access analyzer. With a clinical specificity of 97 percent, the Immulite anti-CCP IgG assay is a highly accurate diagnostic tool for fast and early RA diagnosis. The assay helps rule out other inflammatory and arthritic conditions, enabling physicians

TriLink, QuantiBact ink licensing deal, 7/13:104

TriLink BioTechnologies has signed a licensing agreement with QuantiBact to offer twisted intercalating nucleic acid (TINA) modified oligonucleotides. TINA molecules are intercalators placed at the 5’ end of primers to stabilize duplex formation. Their properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA oligos may find applications wherever an enhanced Tm is required, such as triplex formation or gene silencing. TINA-modified oligonucleotides are now available from TriLink. Visit trilink biotech.com/TINA for up-to-date information. TriLink BioTechnologies, 800-863-6801

Uroplakin II antibody IVD, 7/13:104

Biocare Medical’s uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma. Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor sensitivity. UP II was found to have 79 percent (44/56) sensitivity for bladder urothelial carcinoma compared with 34 percent (19/56)

MRSA/SA test, 7/13:104

Cepheid has received FDA clearance to market its Xpert MRSA/SA blood culture test, which runs on its GeneXpert system, for the detection of methicillin-resistant Staphylococcus aureus and S. aureus in blood culture bottles showing gram-positive cocci in clusters in about one hour. Cepheid’s updated Xpert MRSA/SA BC test processes positive blood culture specimens to determine whether a patient’s blood is infected with MRSA or SA, which are frequent causes of sepsis in hospitalized patients. “Having the capability to differentiate MRSA, S.

CAP 15189 renewal for National Jewish Health, 7/13:104

The College of American Pathologists has renewed CAP 15189 Accreditation for National Jewish Health Advanced Diagnostic Laboratories. The accreditation, based on standard 15189 for laboratory technical competence and continual quality management, is administered by the International Organization for Standardization and seeks to improve patient safety and reduce risk, by outlining standards for quality and competence in medical laboratories. CAP 15189 is a voluntary, non-regulatory accreditation to the ISO 15189:2007 standard as published by ISO. The program complements CAP accreditation and

MARKETPLACE

TRENDING